What Is GLP-1?

Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino acid incretin hormone produced by post-translational processing of proglucagon in intestinal enteroendocrine L-cells. The bioactive forms — GLP-1(7-36) amide and GLP-1(7-37) — are released in response to nutrient ingestion and act as key regulators of glucose homeostasis.

Native GLP-1 has an extremely short half-life of approximately 2-3 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). This rapid turnover has driven decades of research into stabilized GLP-1 analogs with extended half-lives for laboratory study.

The GLP-1 receptor is a class B (secretin family) G-protein-coupled receptor (GPCR) with widespread tissue expression. Key expression sites studied in research models include:

• Pancreatic beta cells: Where GLP-1R activation potentiates glucose-stimulated insulin secretion via cAMP/PKA and cAMP/Epac2 pathways
• Hypothalamic neurons: POMC and NPY/AgRP neurons in the arcuate nucleus express GLP-1R, influencing appetite signaling in research models
• Cardiovascular tissue: Cardiomyocytes, endothelial cells, and vascular smooth muscle cells express GLP-1R
• Central nervous system: Broad CNS expression including hippocampus, cortex, and brainstem — an active area of neuroprotection research

The short half-life of native GLP-1 has led to the development of numerous stabilized analogs for research applications. These analogs employ various strategies to resist DPP-4 degradation:

• Fatty acid acylation: Semaglutide (C-18 fatty diacid) and liraglutide (C-16 fatty acid) bind albumin for extended circulation in research models
• Amino acid substitution: Modifications at position 2 (Aib substitution) resist DPP-4 cleavage
• Dual/triple agonism: Tirzepatide (GLP-1 + GIP) and retatrutide (GLP-1 + GIP + glucagon) engage multiple receptor pathways
• Fc fusion: Dulaglutide fuses GLP-1 to an IgG4 Fc domain for extended stability

Each analog offers distinct pharmacological profiles for comparative receptor binding and signaling studies.

GLP-1 biology is among the most active areas of peptide research, with laboratory investigations spanning multiple disciplines:

• Neuroprotection: GLP-1R activation in neuronal cultures shows reduced oxidative stress markers and improved mitochondrial function
• Beta-cell biology: Effects on proliferation, differentiation, and apoptosis resistance in islet cell models
• Inflammatory signaling: GLP-1R activation modulates NF-kB pathways and inflammatory cytokine release in immune cell cultures
• Biased agonism: Different GLP-1 analogs activate distinct downstream signaling cascades (G-protein vs. beta-arrestin) — a growing field of structure-activity relationship research
• Combination research: GLP-1 with amylin analogs, glucagon co-agonism, and multi-target peptide design